trial

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

NCTId NCT01518894
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 30 (actual)
Sponsored by Biogen
Primary completion 2012-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-11
Primary completion
2012-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-04958242

Sponsors

BiogenLead Sponsor

Sites

1 total
Long Beach, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1
Primary Completion Date
2012-03
Status
COMPLETED
relationships
The graph out of here
drug
PF-04958242
drug
lead_sponsor
Biogen
company
indication
Schizophrenia
indication
Schizophrenia
indication